Literature DB >> 10074645

Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery.

J R Beck1, L B Mongero, R M Kroslowitz, A F Choudhri, J M Chen, J J DeRose, M Argenziano, A J Smerling, M C Oz.   

Abstract

Severe pulmonary hypertension and right-sided circulatory failure (RSCF) represent an increasing cause of morbidity and mortality in patients undergoing high-risk cardiac surgery. Increased pulmonary vascular resistance in the setting of cardiopulmonary bypass (CPB) may further lead to decrease blood flow across the pulmonary vascular bed; thereby decreasing left ventricular filling and cardiac output. Current management techniques for RSCF include both nonspecific vasodilator and inotropic agents (often limited by systemic hypotension) and the placement of right ventricular assist devices (associated with increased perioperative morbidity). Inhaled nitric oxide (NOi) represents a novel, specific pulmonary vasodilator that has been proven efficacious in these clinical settings. We evaluated 34 patients in 38 operations who underwent cardiac surgery at Columbia Presbyterian Medical Center, and who received NOi (20 ppm) through a modified ventilatory circuit for hemodynamically significant elevations in pulmonary vascular resistance. Nine patients underwent cardiac transplantation, three patients bilateral lung transplantation, 16 patients left ventricular assist device placement and 10 patients routine cardiac surgery. Patients receiving NOi exhibited substantial reductions in mean pulmonary artery pressure (mPAP) (34.6 +/- 2.0 to 26.0 +/- 1.7 mmHg, p < 0.0001), with improvements in systemic hemodynamics, mean arterial pressure (68 +/- 3.1 to 75.9 +/- 2.0 mmHg, p = 0.006). In five cases, patients could not be weaned from CPB until NOi was administered. Patients were maintained on NOi from 6 to 240 h postoperatively (median duration 36 h). Inhaled NO induces substantial reductions in mPAP and increases in both cardiac index and systemic blood pressure in patients displaying elevated pulmonary hemodynamics after high-risk cardiac surgery. NO is, therefore, a useful adjunct in these patients in whom acute pulmonary hypertension threatens right ventricular function and hemodynamic stability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074645     DOI: 10.1177/026765919901400106

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  7 in total

Review 1.  Inhaled nitric oxide and pulmonary vasoreactivity.

Authors:  M Aranda; R G Pearl
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

Review 2.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 3.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

Review 4.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

5.  Nitric Oxide as a Unique Bioactive Signaling Messenger in Physiology and Pathophysiology.

Authors:  Narendra Tuteja; Mahesh Chandra; Renu Tuteja; Mithilesh K Misra
Journal:  J Biomed Biotechnol       Date:  2004

Review 6.  Emerging risk factors and prevention of perioperative pulmonary complications.

Authors:  Priyanka Bhateja; Roop Kaw
Journal:  ScientificWorldJournal       Date:  2014-01-21

7.  Impact of right ventricular systolic pressure in elderly patients admitted to intensive care unit after femur fracture surgery: A retrospective observational study.

Authors:  Su Hwan Lee; Yeji Han; Soo Jung Kim; Seok Jeong Lee; Yon Ju Ryu
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.